1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Will Shire's acute HAE drug OK shift dynamic for ViroPharma's prophylactic?

 
• By Donna Young

The US FDA's approval on 25 August of Shire's hereditary angioedema (HAE) drug Firazyr (icatibant) as the first and only self-administered subcutaneous treatment for acute attacks has not only opened the gate for the medicine to claim a favourable chunk of the US market in that indication, but also could have an impact on the prophylactic setting.

The US FDA's approval on 25 August of Shire's hereditary angioedema (HAE) drug Firazyr (icatibant) as the first and only self-administered subcutaneous treatment for acute attacks has not only opened the gate for the medicine to claim a favourable chunk of the US market in that indication, but also could have an impact on the prophylactic setting.

HAE is a rare genetic disorder characterized by intermittent, unpredictable episodes of swelling and pain of the face, extremities, genitals, gastrointestinal tract and most seriously, the larynx, which may result in death by asphyxiation if

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 
• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.

CNS, Cardiometabolics A Bright Spot In Recent Chinese VC/PE Fundings

 
• By Dexter Jie Yan

Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.

Sebela’s Tegoprazan Poised For GERD Market

 
• By Jessica Merrill

Two Phase III trials testing tegoprazan read out positively, but the potassium-competitive acid blocker will compete with Phathom’s Voquezna (vonoprazan).

More from Therapeutic Category

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.